Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy

被引:57
作者
Munir, WM
Pulido, JS
Sharma, MC
Buerk, BM
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Univ Illinois, Chicago Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL USA
来源
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE | 2005年 / 40卷 / 05期
关键词
intravitreal steroids; pars plana vitrectomy; proliferative diabetic retinopathy; proliferative vitreoretinopathy; triamcinolone acetonide;
D O I
10.1016/S0008-4182(05)80052-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: We present a retrospective evaluation of the clinical outcome and complications associated with intravitreal injection of unaltered triamcinolone acetonide in conjunction with pars plana vitrectomy and silicone oil injection for the treatment of complicated proliferative diabetic retinopathy with tractional retinal detachment and severe proliferative vitreoretinopathy. Methods: Thirteen eyes of 12 consecutive patients were identified from a computerized patient database. All eyes were operated on by the same surgeon and received 4 mg of unaltered, commercially available triamcinolone acetonide intravitreally, before silicone oil injection. The patients were followed for a mean of 4.7 months (range 1-15 months), and demographic as well as pertinent preoperative and postoperative clinical information was gathered. Results: At the last follow-up visit, vision had improved in 4 eyes, remained stable in 5 eyes, and worsened in 4 eyes. The retina was attached at the end of follow-up in 10 of the 13 eyes. Eight of the 13 eyes did not show any clinical signs of reproliferation or redetachment during the course of follow-up. The mean intraocular pressure did not increase (preoperative value was 10.8 6.22 mm Hg with a range of 0-22 mm Hg; at last follow-up, mean pressure was 9.6 +/- 3.86 mm Hg with a cumulative postoperative range of 0-26 mm Hg). Steroid crystals were visible at 1 month postoperatively in 3 eyes and did not hinder fundus examination significantly. Interpretation: The intravitreal injection of low-dose, unaltered triamcinolone acetonide in the setting of pars plana vitrectomy and silicone oil injection for the treatment of proliferative vitreoretinopathy and complicated proliferative diabetic retinopathy appears to be well tolerated. Further controlled study is needed to clearly define the potential beneficial effects of intravitreal steroids in these 2 disease processes.
引用
收藏
页码:598 / 604
页数:7
相关论文
共 50 条
  • [41] EFFICACY OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN THE TREATMENT OF VITREOUS HEMORRHAGE RELATED TO PROLIFERATIVE DIABETIC RETINOPATHY
    Chelala, Elias
    Nehme, Joseph
    El Rami, Hala
    Aoun, Roni
    Dirani, Ali
    Fadlallah, Ali
    Jalkh, Alex
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (06): : 1127 - 1133
  • [42] The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy
    Kuo, Hsi-Kung
    Chen, Yi-Hao
    Wu, Pei-Chang
    Kuo, Yu-Hsia
    OPHTHALMOLOGICA, 2015, 233 (3-4) : 198 - 203
  • [43] Pathogenesis and classification of proliferative diabetic vitreoretinopathy
    Kroll, Peter
    Rodrigues, Eduardo Buechele
    Hoerle, Steffen
    OPHTHALMOLOGICA, 2007, 221 (02) : 78 - 94
  • [44] Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy (FIXER) A Randomized Controlled Phase II Trial
    Younes, Ahmed M.
    Hamza, Hany S.
    Omar, Hisham A.
    Abdel-Kader, Ahmed A.
    Abdelbaki, Ahmed M.
    Elnahry, Ayman G.
    OPHTHALMOLOGY RETINA, 2024, 8 (11): : 1044 - 1051
  • [45] Decision Making in Proliferative Diabetic Retinopathy Treatment
    Mary B. Kansora
    Raquel Goldhardt
    Current Ophthalmology Reports, 2019, 7 : 45 - 50
  • [46] Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy
    Flamendorf J.
    Fine H.F.
    Current Ophthalmology Reports, 2014, 2 (4) : 175 - 183
  • [47] Decision Making in Proliferative Diabetic Retinopathy Treatment
    Kansora, Mary B.
    Goldhardt, Raquel
    CURRENT OPHTHALMOLOGY REPORTS, 2019, 7 (01) : 45 - 50
  • [48] INTRAVITREAL TRIAMCINOLONE AS AN ADJUNCT TO STANDARD LASER THERAPY IN COEXISTING HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY AND CLINICALLY SIGNIFICANT MACULAR EDEMA
    Mirshahi, Ahmad
    Shenazandi, Hamideh
    Lashay, Alireza
    Faghihi, Hushang
    Alimahmoudi, Asoo
    Dianat, Seyedsaeid
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (02): : 254 - 259
  • [49] Effect of intravitreal bevacizumab injection before vitrectomy on proliferative diabetic retinopathy
    Li, Cai-Rui
    Sun, Shu-Guang
    Hong, Wei
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2010, 3 (03): : 261 - 263
  • [50] Role of Intravitreal Inflammatory Cytokines and Angiogenic Factors in Proliferative Diabetic Retinopathy
    Zhou, Jinzi
    Wang, Shuhong
    Xia, Xiaobo
    CURRENT EYE RESEARCH, 2012, 37 (05) : 416 - 420